CYTOKINETICS, INCORPORATED APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CYTOKINETICS, INCORPORATED (CYTK) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $36.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $36.37M, a 32.08% increase year-over-year.
- CYTOKINETICS, INCORPORATED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $30.82M, a 30.89% increase year-over-year.
- CYTOKINETICS, INCORPORATED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $30.70M, a 21.06% increase year-over-year.
- CYTOKINETICS, INCORPORATED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $27.54M, a 11.83% increase year-over-year.
- CYTOKINETICS, INCORPORATED apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $112.29M, a 14.76% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $97.84M, a 35.77% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $72.06M, a 50.60% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $47.85M, a 78.34% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.37M 10-Q · filed 2026-08-06 | $67.19M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $30.82M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $112.29M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $30.70M 10-Q · filed 2025-11-05 | $58.23M derived: sum of 2 quarters · filed 2026-08-06 | $81.78M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $27.54M 10-Q · filed 2026-08-06 | $51.08M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $23.55M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $97.84M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $25.36M 10-Q · filed 2025-11-05 | $49.98M derived: sum of 2 quarters · filed 2025-11-05 | $71.59M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $24.62M 10-Q · filed 2025-11-05 | $46.23M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $21.61M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $72.06M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $18.72M 10-Q · filed 2024-11-07 | $37.38M derived: sum of 2 quarters · filed 2024-11-07 | $52.58M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $18.67M 10-Q · filed 2024-11-07 | $33.86M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $15.19M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $47.85M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $13.18M 10-Q · filed 2023-11-03 | $25.37M derived: sum of 2 quarters · filed 2023-11-03 | $34.35M derived: sum of 3 quarters · filed 2023-11-03 | |
| 2022-06-30 | $12.20M 10-Q · filed 2023-11-03 | $21.18M derived: sum of 2 quarters · filed 2023-11-03 | ||
| 2022-03-31 | $8.98M 10-Q · filed 2023-11-03 | |||
| 2021-12-31 | $26.83M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $7.77M 10-Q · filed 2022-11-04 | $14.86M derived: sum of 2 quarters · filed 2022-11-04 | $20.12M derived: sum of 3 quarters · filed 2022-11-04 | |
| 2021-06-30 | $7.09M 10-Q · filed 2022-11-04 | $12.35M derived: sum of 2 quarters · filed 2022-11-04 | ||
| 2021-03-31 | $5.26M 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | $17.62M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $4.69M 10-Q · filed 2021-11-05 | $9.22M derived: sum of 2 quarters · filed 2021-11-05 | $12.74M derived: sum of 3 quarters · filed 2021-11-05 | |
| 2020-06-30 | $4.53M 10-Q · filed 2021-11-05 | $8.05M derived: sum of 2 quarters · filed 2021-11-05 | ||
| 2020-03-31 | $3.52M 10-Q · filed 2021-11-05 | |||
| 2019-12-31 | $10.76M 10-K · filed 2022-02-25 | |||
| 2019-09-30 | $2.78M 10-Q · filed 2020-11-06 | $5.60M derived: sum of 2 quarters · filed 2020-11-06 | $7.88M derived: sum of 3 quarters · filed 2020-11-06 | $10.16M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $2.82M 10-Q · filed 2020-11-06 | $5.10M derived: sum of 2 quarters · filed 2020-11-06 | $7.38M derived: sum of 3 quarters · filed 2021-02-26 | $9.95M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $2.28M 10-Q · filed 2020-11-06 | $4.56M derived: sum of 2 quarters · filed 2021-02-26 | $7.13M derived: sum of 3 quarters · filed 2021-02-26 | $9.64M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $4.85M derived: sum of 2 quarters · filed 2021-02-26 | $7.36M derived: sum of 3 quarters · filed 2021-02-26 | $9.76M 10-K · filed 2021-02-26 |
| 2018-09-30 | $2.57M 10-Q · filed 2019-11-01 | $5.08M derived: sum of 2 quarters · filed 2019-11-01 | $7.48M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $2.50M 10-Q · filed 2019-11-01 | $4.91M derived: sum of 2 quarters · filed 2019-11-01 | ||
| 2018-03-31 | $2.40M 10-Q · filed 2019-11-01 | |||
| 2017-12-31 | $9.03M 10-K · filed 2019-03-07 | |||
| 2016-12-31 | $7.15M 10-K · filed 2018-03-05 | |||
| 2015-12-31 | $4.57M 10-K · filed 2018-03-05 | |||
| 2014-12-31 | $3.33M 10-K · filed 2017-03-06 | |||
| 2013-12-31 | $3.60M 10-K · filed 2016-03-03 | |||
| 2012-12-31 | $3.78M 10-K · filed 2015-03-06 | |||
| 2011-12-31 | $3.07M 10-K · filed 2014-03-07 | |||
| 2010-12-31 | $4.02M 10-K · filed 2013-03-15 | |||
| 2009-12-31 | $4.91M 10-K · filed 2013-03-15 | |||
| 2008-12-31 | $5.28M 10-K · filed 2013-03-15 | |||
| 2007-12-31 | $4.83M 10-K · filed 2013-03-15 | |||
| 2006-12-31 | $3.42M 10-K · filed 2013-03-15 | |||
| 2005-12-31 | $67.00K 10-K · filed 2013-03-15 | |||
| 2004-12-31 | $278.00K 10-K · filed 2013-03-15 | |||
| 2003-12-31 | $158.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |